← Human Trials & Peer-Reviewed Studies
Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction.
Plain-language guide to PMID 19584187 (2009): single-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 19584187
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Cittadini A et al. (12 authors)
- DOI
- 10.1210/jc.2009-0533
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
The aim of the current study was to investigate the prevalence of GH deficiency in a patient population with CHF and evaluate the cardiovascular effects of GH replacement therapy.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
One hundred fifty-eight patients with CHF, New York Heart Association class II-IV, underwent a GH stimulation test.
Sixty-three patients satisfied the criteria for GH deficiency, and 56 of them were enrolled in the trial.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.
The randomized, single-blind, controlled trial was conducted at the Federico II University.
What Was Measured
The subject headings attached to it are Affect, Exercise Test, Heart Failure, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I and Natriuretic Peptide, Brain.
What This Means in Plain Language
The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.